DK1296713T3 - Immunstimulerende oligodeoxynukleotider - Google Patents
Immunstimulerende oligodeoxynukleotiderInfo
- Publication number
- DK1296713T3 DK1296713T3 DK01960277T DK01960277T DK1296713T3 DK 1296713 T3 DK1296713 T3 DK 1296713T3 DK 01960277 T DK01960277 T DK 01960277T DK 01960277 T DK01960277 T DK 01960277T DK 1296713 T3 DK1296713 T3 DK 1296713T3
- Authority
- DK
- Denmark
- Prior art keywords
- deoxyribosepurine
- deoxycytosine
- deoxyinosine
- deoxyguanosine
- deoxyadenosine
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 title abstract 2
- RPFPNGBGDKGFRI-XLPZGREQSA-N 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methyl-3h-purin-6-one Chemical compound C12=NC(C)=NC(O)=C2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 RPFPNGBGDKGFRI-XLPZGREQSA-N 0.000 abstract 2
- FERYXNKLCFJNMG-QJPTWQEYSA-N (2r,3s,5r)-2-(hydroxymethyl)-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-3-ol Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 FERYXNKLCFJNMG-QJPTWQEYSA-N 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract 1
- COVHWGAKPGOZBI-QJPTWQEYSA-N [(2r,3s,5r)-3-hydroxy-5-[6-(3-methylbut-3-enylamino)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCC(=C)C)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 COVHWGAKPGOZBI-QJPTWQEYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
| AT19732000 | 2000-11-23 | ||
| PCT/EP2001/006433 WO2001093905A1 (en) | 2000-06-08 | 2001-06-07 | Immunostimulatory oligodeoxynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1296713T3 true DK1296713T3 (da) | 2004-01-26 |
Family
ID=25608484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01960277T DK1296713T3 (da) | 2000-06-08 | 2001-06-07 | Immunstimulerende oligodeoxynukleotider |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8568742B2 (hu) |
| EP (1) | EP1296713B1 (hu) |
| JP (2) | JP5271471B2 (hu) |
| KR (1) | KR100799788B1 (hu) |
| CN (1) | CN1309418C (hu) |
| AT (1) | ATE249839T1 (hu) |
| AU (2) | AU2001281812B2 (hu) |
| BR (1) | BRPI0111639B8 (hu) |
| CA (1) | CA2411575C (hu) |
| CZ (1) | CZ304195B6 (hu) |
| DE (1) | DE60100814T2 (hu) |
| DK (1) | DK1296713T3 (hu) |
| ES (1) | ES2206424T3 (hu) |
| HK (1) | HK1056678A1 (hu) |
| HU (1) | HU228264B1 (hu) |
| IL (2) | IL152959A0 (hu) |
| IS (1) | IS1993B (hu) |
| MX (1) | MXPA02012010A (hu) |
| NO (1) | NO329492B1 (hu) |
| PL (1) | PL211036B1 (hu) |
| PT (1) | PT1296713E (hu) |
| RU (2) | RU2293573C2 (hu) |
| SI (1) | SI1296713T1 (hu) |
| SK (1) | SK287689B6 (hu) |
| TR (1) | TR200302015T4 (hu) |
| WO (1) | WO2001093905A1 (hu) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| DK1296713T3 (da) * | 2000-06-08 | 2004-01-26 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Immunstimulerende oligodeoxynukleotider |
| EP1350262B8 (en) * | 2000-12-08 | 2008-08-13 | Coley Pharmaceuticals GmbH | Cpg-like nucleic acids and methods of use thereof |
| JP2004519452A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
| WO2002053185A2 (en) * | 2001-01-05 | 2002-07-11 | Intercell Ag | Anti-inflammatory use of polycationic compounds |
| US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
| US20040081655A1 (en) * | 2001-01-05 | 2004-04-29 | Karen Lingnau | Methods and compositions comprising polycationic compounds |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| WO2002095027A2 (en) * | 2001-05-21 | 2002-11-28 | Intercell Ag | Immunostimulatory oligodeoxynucleic molecules |
| CN1642982A (zh) * | 2001-07-26 | 2005-07-20 | 唐诚公司 | 活化或抑制类Toll受体9的试剂 |
| US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
| AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| AU2002358616A1 (en) * | 2001-12-07 | 2003-06-17 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
| US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
| US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
| JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
| US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
| EP2314603A3 (en) | 2002-10-15 | 2011-05-18 | Intercell AG | Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof |
| SI1601770T1 (sl) | 2003-03-04 | 2010-01-29 | Intercell Ag | Streptococcus pyogenes antigeni |
| DE602004029657D1 (de) | 2003-03-24 | 2010-12-02 | Intercell Ag | Verbesserte impfstoffe |
| JP2006521321A (ja) * | 2003-03-24 | 2006-09-21 | インターツェル・アクチェンゲゼルシャフト | 免疫応答を促進するためのミョウバンおよびＴｈ１免疫応答誘起アジュバントの使用 |
| US7628994B2 (en) | 2003-03-31 | 2009-12-08 | Intercell Ag | S. epidermidis antigens |
| WO2004092209A2 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
| US7438912B2 (en) | 2003-05-07 | 2008-10-21 | Intercell Ag | S.agalactiae antigens I + II |
| CA2525540A1 (en) | 2003-05-30 | 2004-12-09 | Intercell Ag | Enterococcus antigens |
| CA2530062A1 (en) * | 2003-07-11 | 2005-01-20 | Intercell Ag | Hcv vaccines |
| JP4817599B2 (ja) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | 免疫活性増強剤とこれを用いた免疫活性の増強方法 |
| KR100721928B1 (ko) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
| DK1931379T3 (da) | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| EP2040745B1 (en) | 2006-06-28 | 2012-12-05 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| EP2059531A1 (en) | 2006-07-07 | 2009-05-20 | Intercell AG | Small streptococcus pyogenes antigens and their use |
| EP2287176A1 (en) | 2006-09-15 | 2011-02-23 | Intercell AG | Borrelia antigens |
| EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| EP2269625A3 (en) | 2007-01-12 | 2012-08-08 | Intercell AG | Protective proteins of S. agalactiae, combinations thereof and methods of using the same |
| EP2338902A1 (en) | 2007-05-02 | 2011-06-29 | Intercell AG | Klebsiella antigens |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| EP2167530A2 (en) | 2007-06-18 | 2010-03-31 | Intercell AG | Chlamydia antigens |
| WO2009115508A2 (en) | 2008-03-17 | 2009-09-24 | Intercell Ag | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| CN102316894A (zh) | 2008-06-20 | 2012-01-11 | 惠氏有限责任公司 | 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法 |
| EP2424882A2 (en) | 2009-02-05 | 2012-03-07 | Intercell AG | Peptides protective against e. faecalis, methods and uses relating thereto |
| US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
| SI2445522T1 (sl) | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
| US9125951B2 (en) | 2009-06-22 | 2015-09-08 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| JP2013503148A (ja) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント |
| EP2319871A1 (en) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| EP2308896A1 (en) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| PE20121689A1 (es) | 2009-10-09 | 2012-12-14 | Sanofi Sa | Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos |
| US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
| US20130071422A1 (en) | 2010-03-18 | 2013-03-21 | Michele Pallaoro | Adjuvanted vaccines for serogroup b meningococcus |
| SI3170508T1 (sl) | 2010-06-04 | 2020-01-31 | Wyeth Llc | Formulacije cepiva |
| HRP20210242T4 (hr) | 2010-08-23 | 2024-05-10 | Wyeth Llc | Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086 |
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| AR082925A1 (es) | 2010-09-08 | 2013-01-16 | Medigene Ag | Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados |
| CN103096920B (zh) | 2010-09-10 | 2016-03-23 | 惠氏有限责任公司 | 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体 |
| CA2819120C (en) | 2010-12-22 | 2016-07-05 | Wyeth Llc | Stable immunogenic compositions of staphylococcus aureus antigens |
| WO2012160183A1 (en) * | 2011-05-26 | 2012-11-29 | Intervet International B.V. | Immunostimulatory oligodeoxynucleotides |
| BR112013029966A2 (pt) * | 2011-05-26 | 2017-01-31 | Intervet Int Bv | oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, e, vacina para prevenir ou combater uma doença infecciosa |
| ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
| BR122016004924A2 (pt) | 2012-03-09 | 2019-07-30 | Pfizer Inc. | Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| HRP20221438T1 (hr) | 2012-12-20 | 2023-02-03 | Pfizer Inc. | Postupak glikokonjugiranja |
| JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
| CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
| CA2948455C (en) | 2014-05-09 | 2023-09-19 | Universiteit Utrecht Holding B.V. | New cath2 derivatives |
| AU2016221318B2 (en) | 2015-02-19 | 2020-06-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| JP2021513840A (ja) | 2018-02-16 | 2021-06-03 | ２エー ファーマ アーベー | 自己免疫疾患の処置のためのパルボウイルス構造タンパク質 |
| EP3527223A1 (en) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutated parvovirus structural protein |
| SG11202110646PA (en) | 2019-05-20 | 2021-10-28 | Valneva Se | A subunit vaccine for treatment or prevention of a respiratory tract infection |
| EP3980056A4 (en) | 2019-05-31 | 2023-03-29 | Universidad De Chile | IMMUNOGENIC FORMULATION THAT INDUCES PROTECTION AGAINST SHIGA TOXIN-PRODUCING ESCHERICHIA COLI (STEC). |
| US20230146256A1 (en) | 2020-04-17 | 2023-05-11 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
| CA3192786A1 (en) | 2020-08-26 | 2022-03-03 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| CA3194598A1 (en) | 2020-10-07 | 2022-04-14 | Valentina SCREPANTI-SUNDQUIST | Cholera vaccine formulation |
| WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3725545A (en) | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
| US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| CA2016841C (en) * | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| ZA908001B (en) | 1989-10-11 | 1991-08-28 | Merrell Dow Pharma | Inosine/guanosine derivatives as immunosuppressive agents |
| US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| ES2101083T3 (es) * | 1990-12-21 | 1997-07-01 | Hoffmann La Roche | Tipado del dna hla dqbeta. |
| US5098437A (en) * | 1991-02-13 | 1992-03-24 | Pfizer Hospital Products Group, Inc. | Acetabular cup positioning insert |
| ATE198773T1 (de) | 1991-10-23 | 2001-02-15 | Baylor College Medicine | Fingerabdruckartige identifikation von bakterienstämmen mittels amplifikation repetitiver dna-sequenzen |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US20020081577A1 (en) * | 1995-06-06 | 2002-06-27 | Robert L. Kilkuskie | Oligonucleotides speciific for hepatitis c virus |
| JP4484967B2 (ja) * | 1995-06-06 | 2010-06-16 | ベス イスラエル ディーコネス メディカル センター | Ｄｎａ診断試験の方法及び装置 |
| ZA964446B (en) * | 1995-06-06 | 1996-12-06 | Hoffmann La Roche | Oligonucleotides specific for hepatitis c virus |
| CA2267648A1 (en) | 1996-10-02 | 1998-04-09 | David Kilpatrick | Detection and identification of non-polio enteroviruses |
| EP1537877A3 (en) * | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| ES2326848T3 (es) | 1997-06-06 | 2009-10-20 | The Regents Of The University Of California | Inhibidores de la actividad de secuencias inmunoestimulatorias de adn. |
| US5955443A (en) * | 1998-03-19 | 1999-09-21 | Isis Pharmaceuticals Inc. | Antisense modulation of PECAM-1 |
| US6001651A (en) * | 1998-03-20 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of LFA-3 |
| IL126919A0 (en) * | 1998-11-05 | 1999-09-22 | Univ Ben Gurion | Antisense oligomer |
| NZ508797A (en) * | 1998-06-24 | 2004-02-27 | Innogenetics N | Particles of HCV envelope proteins: use for vaccination |
| DE60022665T2 (de) | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
| ATE292638T1 (de) | 2000-05-01 | 2005-04-15 | Hybridon Inc | Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside |
| DK1296713T3 (da) * | 2000-06-08 | 2004-01-26 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Immunstimulerende oligodeoxynukleotider |
| AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| DE602004029657D1 (de) * | 2003-03-24 | 2010-12-02 | Intercell Ag | Verbesserte impfstoffe |
| US7951845B2 (en) * | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
-
2001
- 2001-06-07 DK DK01960277T patent/DK1296713T3/da active
- 2001-06-07 AU AU2001281812A patent/AU2001281812B2/en not_active Expired
- 2001-06-07 IL IL15295901A patent/IL152959A0/xx active IP Right Grant
- 2001-06-07 TR TR200302015T patent/TR200302015T4/xx unknown
- 2001-06-07 WO PCT/EP2001/006433 patent/WO2001093905A1/en active IP Right Grant
- 2001-06-07 JP JP2002501476A patent/JP5271471B2/ja not_active Expired - Lifetime
- 2001-06-07 RU RU2003100409A patent/RU2293573C2/ru active
- 2001-06-07 SK SK1815-2002A patent/SK287689B6/sk not_active IP Right Cessation
- 2001-06-07 SI SI200130047T patent/SI1296713T1/xx unknown
- 2001-06-07 BR BRPI0111639A patent/BRPI0111639B8/pt not_active IP Right Cessation
- 2001-06-07 CA CA2411575A patent/CA2411575C/en not_active Expired - Lifetime
- 2001-06-07 CN CNB018107974A patent/CN1309418C/zh not_active Expired - Lifetime
- 2001-06-07 CZ CZ2002-4168A patent/CZ304195B6/cs not_active IP Right Cessation
- 2001-06-07 RU RU2007103151A patent/RU2413520C2/ru active
- 2001-06-07 EP EP20010960277 patent/EP1296713B1/en not_active Expired - Lifetime
- 2001-06-07 AU AU8181201A patent/AU8181201A/xx active Pending
- 2001-06-07 MX MXPA02012010A patent/MXPA02012010A/es active IP Right Grant
- 2001-06-07 AT AT01960277T patent/ATE249839T1/de active
- 2001-06-07 DE DE2001600814 patent/DE60100814T2/de not_active Expired - Lifetime
- 2001-06-07 KR KR20027016711A patent/KR100799788B1/ko active IP Right Grant
- 2001-06-07 HU HU0301229A patent/HU228264B1/hu unknown
- 2001-06-07 US US10/297,555 patent/US8568742B2/en active Active
- 2001-06-07 PL PL358982A patent/PL211036B1/pl unknown
- 2001-06-07 PT PT01960277T patent/PT1296713E/pt unknown
- 2001-06-07 ES ES01960277T patent/ES2206424T3/es not_active Expired - Lifetime
-
2002
- 2002-11-18 IS IS6627A patent/IS1993B/is unknown
- 2002-11-20 IL IL152959A patent/IL152959A/en unknown
- 2002-12-04 NO NO20025835A patent/NO329492B1/no not_active IP Right Cessation
-
2003
- 2003-12-11 HK HK03109011A patent/HK1056678A1/xx not_active IP Right Cessation
-
2013
- 2013-01-10 JP JP2013002571A patent/JP5908851B2/ja not_active Expired - Lifetime
- 2013-03-06 US US13/786,815 patent/US8945591B2/en not_active Expired - Fee Related
-
2014
- 2014-12-30 US US14/585,740 patent/US9492537B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1296713T3 (da) | Immunstimulerende oligodeoxynukleotider | |
| DE60221004D1 (de) | Immunostimulierende oligodeoxyribonuklein moleküle | |
| ES2569927T3 (es) | Oligonucleótidos inmunomoduladores estabilizados | |
| DE69838449D1 (de) | Aminooxy-modifizierte oligonukleotide | |
| CY1108158T1 (el) | Ολιγονουκλεοτιδιο ν3'→ρ5' θειoφωσφοραμιδικα: συνθεση αυτων και χρηση | |
| Prakash et al. | 2 ‘-O-[2-(Guanidinium) ethyl]-modified oligonucleotides: stabilizing effect on duplex and triplex structures | |
| DE69403642T2 (de) | 7-deazapurin modifizierte oligonukleotide | |
| CY1112420T1 (el) | Ρυθμιση της γονιδιακης εκφρασης στα φυτα με μεσολαβηση dsrνα | |
| IL151928A (en) | Preparation, pharmaceutical preparations and uses of rna-specific rna disorder mediators | |
| ES2118593T3 (es) | Analogos de nucleotidos de pteridina como sondas fluorescentes de adn. | |
| CO5070674A1 (es) | Vacunas con un oligonucleotido cpg como adyuvante | |
| Quant et al. | Chemical synthesis of 13C-labelled monomers for the solid-phase and template controlled enzymatic synthesis of DNA and RNA oligomers | |
| CY1106041T1 (el) | Καινοφανης συλλεκτινη | |
| BRPI0415496A (pt) | microdisposição de oligonucleotìdeo | |
| ATE242261T1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
| NO972868L (no) | Oligonukleotid-dendrimer konjugater | |
| KR960700262A (ko) | 이합체 블록의 합성 및 그것의 올리고누클레오티드 어셈블리에의 사용 방법(synthesis of dimmer blocks and their use in assembling oligonucleotides) | |
| Hartel et al. | Substitution of Adenine by Purine‐2, 6‐diamine Improves the Nonenzymatic Oligomerization of Ribonucleotides on Templates Containing Thymidine | |
| WO2000040605A3 (en) | Compositions and methods relating to cyclic compounds that undergo nucleotide base pair-specific interactions with double-stranded nucleic acids | |
| BR0207566A (pt) | Processo para preparação de (e)-5-(2-bromovinil)-2'-desoxiuridina | |
| DE69928543D1 (de) | Pteridine-nukleotid-analoge | |
| DE60216960D1 (de) | Verfahren zur herstellung von beta-1,3-n-acetylglucosamin-transferase und einer n-acetylglucosamin enthaltenden saccharidzusammensetzung | |
| EP1950296A3 (en) | Oligodeoxynucleotide and its use to induce an immune response |